

# Mycoplasma pneumoniae IgM ELISA

Enzyme immunoassays (microtiter strips) for the qualitative and quantitative determination of IgM antibodies against *Mycoplasma pneumoniae* in human serum and plasma.

**REF**

**RE56681**



**12x8**



**2-8°C**

EU:

**IVD**



U.S.: *For research use only.  
Not for use in diagnostic procedures.*



**I B L I N T E R N A T I O N A L G M B H**

Flughafenstrasse 52a  
D-22335 Hamburg, Germany

Phone: +49 (0)40-53 28 91-0  
Fax: +49 (0)40-53 28 91-11

IBL@IBL-International.com  
www.IBL-International.com

## 1. INTENDED USE

Enzyme immunoassays (microtiter strips) for the qualitative and quantitative determination of IgM antibodies against *Mycoplasma pneumoniae* in human serum and plasma.

## 2. SUMMARY AND EXPLANATION

*Mycoplasma pneumoniae* is besides various viruses like rhinovirus, coronavirus, influenza, parainfluenza or adenovirus the reason for the classical common cold.

Mycoplasmas belong to the Mollicutes class. Common characteristics of the six eubacterial genera is the lack of a bacterial cell wall, osmotic fragility and small dimensions. The genome is significantly smaller compared to gram-positive and gram-negative bacteria. They depend on a host cell, respectively, on a host organism like a parasite.

*Mycoplasma pneumoniae* is a human pathogenic bacterium causing tracheobronchitis and primary atypical pneumonia. Also secondary diseases like infarction, encephalitis, chronic neuropathy and the Guillain-Barre syndrome sometimes occur with a *M. pneumoniae* infection.

In the laboratory, besides the cold agglutinin test and complement fixation reaction (CF), the ELISA is the method of choice showing an excellent sensitivity and the possibility to differentiate between the immunoglobulin classes.

Specific IgA antibodies are developed more regularly and more rapidly than IgM during an acute infection. IgA titres also decrease earlier than IgM or the late-peaking IgG response. Various studies showed that the determination of all the three immunoglobulin classes is necessary to monitor each step of the clinical course.

## 3. TEST PRINCIPLE

Solid phase enzyme-linked immunosorbent assay (ELISA) based on the sandwich principle. The wells are coated with antigen. Specific antibodies of the sample binding to the antigen coated wells are detected by a secondary enzyme conjugated antibody (E-Ab) specific for human IgM. After the substrate reaction the intensity of the color developed is proportional to the amount of IgM-specific antibodies detected. Results of samples can be determined directly using the standard curve.

## 4. WARNINGS AND PRECAUTIONS


1. For *in-vitro diagnostic* use only. For professional use only.
2. Before starting the assay, read the instructions completely and carefully. Use the valid version of the package insert provided with the kit. Be sure that everything is understood.
3. In case of severe damage of the kit package please contact IBL or your supplier in written form, latest one week after receiving the kit. Do not use damaged components in test runs, but keep safe for complaint related issues.
4. Obey lot number and expiry date. Do not mix reagents of different lots. Do not use expired reagents.
5. Follow good laboratory practice and safety guidelines. Wear lab coats, disposable latex gloves and protective glasses where necessary.
6. Reagents of this kit containing hazardous material may cause eye and skin irritations. See MATERIALS SUPPLIED and labels for details. Material Safety Data Sheets for this product are available on the IBL-Homepage or upon request directly from IBL.
7. Chemicals and prepared or used reagents have to be treated as hazardous waste according to national biohazard and safety guidelines or regulations.
8. Avoid contact with Stop solution. It may cause skin irritations and burns.
9. Some reagents contain sodium azide (NaN<sub>3</sub>) as preservatives. In case of contact with eyes or skin, flush immediately with water. NaN<sub>3</sub> may react with lead and copper plumbing to form explosive metal azides. When disposing reagents, flush with a large volume of water to avoid azide build-up.
10. All reagents of this kit containing human serum or plasma have been tested and were found negative for anti-HIV I/II, HBsAg and anti-HCV. However, a presence of these or other infectious agents cannot be excluded absolutely and therefore reagents should be treated as potential biohazards in use and for disposal.




## 9. PROCEDURE NOTES

1. Any improper handling of samples or modification of the test procedure may influence the results. The indicated pipetting volumes, incubation times, temperatures and pretreatment steps have to be performed strictly according to the instructions. Use calibrated pipettes and devices only.
2. Once the test has been started, all steps should be completed without interruption. Make sure that required reagents, materials and devices are prepared ready at the appropriate time. Allow all reagents and specimens to reach room temperature (18-25 °C) and gently swirl each vial of liquid reagent and sample before use. Mix reagents without foaming.
3. Avoid contamination of reagents, pipettes and wells/tubes. Use new disposable plastic pipette tips for each component and specimen. Do not interchange caps. Always cap not used vials. Do not reuse wells/tubes or reagents.
4. Use a pipetting scheme to verify an appropriate plate layout.
5. Incubation time affects results. All wells should be handled in the same order and time sequences. It is recommended to use an 8-channel Micropipettor for pipetting of solutions in all wells.
6. Microplate washing is important. Improperly washed wells will give erroneous results. It is recommended to use a multichannel pipette or an automatic microplate washing system. Do not allow the wells to dry between incubations. Do not scratch coated wells during rinsing and aspiration. Rinse and fill all reagents with care. While rinsing, check that all wells are filled precisely with Wash Buffer, and that there are no residues in the wells.
7. Humidity affects the coated wells/tubes. Do not open the pouch until it reaches room temperature. Unused wells/tubes should be returned immediately to the resealed pouch including the desiccant.

## 10. PRE-TEST SETUP INSTRUCTIONS

	In order to avoid interferences of specific IgG and rheumatoid factors, patient sera should be treated with RF absorbent (REF KIRF561).
---	---

### 10.1. Preparation of Components

	The contents of the kit for 96 determinations can be divided into 3 separate runs. The volumes stated below are for one run with 4 strips (32 determinations).
---	--

Dilute / dissolve	Component		Diluent	Relation	Remarks	Storage	Stability
20 mL	<b>WASHBUF</b> <b>CONC</b>	200 mL	bidist. water	1:11	Warm up at 37 °C to dissolve crystals, if necessary. Mix vigorously.	2-8 °C	8 w
1 mL	RF-Absorbent	20 mL	<b>DILBUF</b>	1:21	Incubate ≥ 1 min.	2-8 °C	8 w

### 10.2. Dilution of Samples

Sample	to be diluted	with	Relation	Remarks
<b>Serum / Plasma</b>	generally	<b>DILBUF</b> (+ RF-Absorbent)	1:101	e.g. 5 µL + 500 µL <b>DILBUF</b>

Samples containing concentrations higher than the highest standard have to be diluted further.

Samples with RF-Absorbent: Do not incubate >20 min to avoid adsorption of specific antibodies.

Pretreated samples may be turbid.

## 11. TEST PROCEDURE

1.	Pipette <b>100 µL</b> of each <b>Standard and diluted sample</b> into the respective wells of the Microtiter Plate. In the qualitative test only Standard B is used.
2.	Cover plate with adhesive foil. Incubate <b>60 min</b> at <b>18-25 °C</b> .
3.	Remove adhesive foil. Discard incubation solution. Wash plate <b>3 x</b> with <b>300 µL</b> of <b>diluted Wash Buffer</b> . Remove excess solution by tapping the inverted plate on a paper towel.
4.	Pipette <b>100 µL</b> of <b>Enzyme Conjugate</b> into each well.
5.	Cover plate with new adhesive foil. <b>Incubate 30 min</b> at <b>18-25 °C</b> .
6.	Remove adhesive foil. Discard incubation solution. Wash plate <b>3 x</b> with <b>300 µL</b> of <b>diluted Wash Buffer</b> . Remove excess solution by tapping the inverted plate on a paper towel.
7.	For adding of Substrate and Stop Solution use, if available, an 8-channel Micropipettor. Pipetting should be carried out in the same time intervals for Substrate and Stop Solution. Use positive displacement and avoid formation of air bubbles.
8.	Pipette <b>100 µL</b> of <b>TMB Substrate Solution</b> into each well.
9.	Incubate <b>20 min</b> at <b>18-25 °C</b> in the dark (without adhesive foil).
10.	Stop the substrate reaction by adding <b>100 µL</b> of <b>TMB Stop Solution</b> into each well. Briefly mix contents by gently shaking the plate. Color changes from blue to yellow.
11.	<b>Measure</b> optical density with a photometer at <b>450 nm</b> (Reference-wavelength: 600-650 nm) within <b>60 min</b> after pipetting of the Stop Solution.

## 12. QUALITY CONTROL

The test results are only valid if the test has been performed following the instructions. Moreover the user must strictly adhere to the rules of GLP (Good Laboratory Practice) or other applicable standards/laws. All standards/controls must be found within the acceptable ranges as stated on the QC Certificate. If the criteria are not met, the run is not valid and should be repeated. Each laboratory should use known samples as further controls. It is recommended to participate at appropriate quality assessment trials.

In case of any deviation the following technical issues should be proven: Expiration dates of (prepared) reagents, storage conditions, pipettes, devices, incubation conditions and washing methods.

## 13. CALCULATION OF RESULTS

The evaluation of the test can be performed either quantitatively or qualitatively.

### 13.1. Qualitative Evaluation

The Cut-off value is given by the optical density (OD) of the Standard B (Cut-off standard). The Cut-off index (COI) is calculated from the mean optical densities of the sample and Cut-off value. If the optical density of the sample is within a range of 20 % around the Cut-off value (grey zone), the sample has to be considered as borderline. Samples with higher ODs are positive, samples with lower ODs are negative.

For a quantification, the Cut-off index (COI) of the samples can be formed as follows:

$$\text{COI} = \frac{\text{OD Sample}}{\text{OD Standard B}}$$

### 13.2. Quantitative Evaluation

The obtained OD of the standards (y-axis, linear) are plotted against their concentration (x-axis, logarithmic) either on semi-logarithmic graph paper or using an automated method. A good fit is provided with cubic spline or point-to-point curve, because these methods give the highest accuracy in the data calculation.

For the calculation of the standard curve, apply each signal of the standards (one obvious outlier of duplicates might be omitted and the more plausible single value might be used).

The concentration of the samples can be read directly from the standard curve.


The initial dilution has been taken into consideration when reading the results from the graph. Results of samples of higher predilution have to be multiplied with the dilution factor.

Samples showing concentrations above the highest standard have to be diluted as described in PRE-TEST SETUP INSTRUCTIONS and reassayed.

### Typical Calibration Curve

(Example. Do not use for calculation!)

Standard	U/mL	OD <sub>Mean</sub>
A	1	0.022
B	10	0.344
C	35	0.724
D	125	1.492



## 14. INTERPRETATION OF RESULTS

Method	Range	Interpretation
Quantitative (Standard curve)	< 8 U/mL	negative
	8 – 12 U/mL	equivocal
	> 12 U/mL	positive
Qualitative (Cut-off Index, COI)	< 0.8	negative
	0.8 – 1.2	equivocal
	> 1.2	positive

The results themselves should not be the only reason for any therapeutical consequences. They have to be correlated to other clinical observations and diagnostic tests.

## 15. EXPECTED VALUES

In an in-house study, apparently healthy subjects showed the following results:

Ig Isotype	n	Interpretation		
		positive	equivocal	negative
IgM	56	5.4 %	5.4 %	89.3 %

## 16. LIMITATIONS OF THE PROCEDURE

Specimen collection has a significant effect on the test results. See SPECIMEN COLLECTION AND STORAGE for details.

Azide and thimerosal at concentrations > 0.1 % interfere in this assay and may lead to false results.

The following blood components do not have a significant effect (+/-20 % of expected) on the test results up to the below stated concentrations:

Hemoglobin	8.0 mg/mL
Bilirubin	0.3 mg/mL
Triglyceride	5.0 mg/mL

## 17. PERFORMANCE

<b>Precision</b>	Mean (U/mL)	CV (%)	
	Intra-Assay	38	7.9
	Inter-Assay	30	8.0
<b>Linearity</b>	Range (U/mL)	Serial dilution up to	Range (%)
	4.6 – 83	1/8	70 - 106
<b>Recovery</b>	91 – 116 %	% Recovery after spiking (n = 3)	
<b>Method Comparison versus ELISA</b>	Rel. Sensitivity	> 95 %	
	Rel. Specificity	> 95 %	

**18. PRODUCT LITERATURE REFERENCES**

1. Ansari MHK, Rasmi Y, Manafi M, Rahimpour A, Ghadermarzi E, The Evaluation of Helicobacter pylori infection and cardiovascular disease risk factors with arteriosclerosis, *Urmia Medical J* 14(9): 788-791 (2010)
2. Chaudhry R, Varshney AK, Malhotra P, Adhesion proteins of Mycoplasma pneumoniae, *Front Biosci* 1 (12): 690-9 (2007)
3. Chia WK, Spence L, Dunkley L, Bradbury W, Development of urease conjugated enzyme-linked immunosorbent assays (ELISA) for the detection of IgM and IgG antibodies against Mycoplasma pneumoniae in human sera, *Diagn Microbiol Infect Dis* 11: 101-7 (1988)
4. Clyde WA, Clinical overview of typical Mycoplasma pneumoniae infections, *Clin Infect Dis* 17: 32-36 (1993)
5. Daxboeck F, Krause R, Wenisch C, Laboratory diagnosis of Mycoplasma pneumoniae infection, *Clin Microbiol Infect* 9(4): 263-73 (2003)
6. Döller G, Döller PC, Jacobs E, Schuy W, Zur Differentialdiagnostik von Infektionen des Respirationstrakts, *Diagnose & Labor* 43: 21-33 (1993)
7. Drasbek M, Nielsen PK, Persson K, Birkelund S, Christiansen G, Immune response to Mycoplasma pneumoniae P1 and P116 in patients with atypical pneumonia analyzed by ELISA, *BMC Microbiol* 4: 1-10 (2004)
8. Dumke R, Von Baum H, Lück PC, Jacobs E, Subtypes and variants of Mycoplasma pneumoniae: local and temporal changes in Germany 2003-2006 and absence of a correlation between the genotype in the respiratory tract and the occurrence of genotype-specific antibodies in the sera of infected patients, *Epidemiol Infect* 138(12): 1829-37 (2010)
9. Ferwerda A, Moll HA, de Groot R, Respiratory tract infections by Mycoplasma pneumoniae in children: a review of diagnostic and therapeutic measures, *Eur J Pediatr* 160: 483-491 (2001)
10. Granström M, Holme T, Sjögren AM, Örtqvist A, Kalin M: The role of IgA determination by ELISA in the early serodiagnosis of Mycoplasma pneumoniae infection, in relation to IgG and  $\mu$ -capture IgM methods, *Med Microbiol.* 40: 288-292 (1994)
11. Hammerschlag MR, Mycoplasma pneumoniae infections, *Curr Opin Infect Dis* 14: 181-186 (2001)
12. Hirschberg L, Holme T, Krook A, Vikerfors T, IgG response to Mycoplasma pneumoniae in patients with communityacquired pneumonia determined by ELISA, *APMIS* 96: 605-10 (1988)
13. Jacobs E, Mycoplasma pneumoniae: now in the focus of clinicians and epidemiologists, *Eurosurveillance* 17 (6): 1-3 (2012)
14. Seggev JS, Sedmak GV, Kurup VP, Isotype-specific antibody responses to acute Mycoplasma pneumoniae infection, *J Ann Allergy Asthma Immunol* 77: 67-73 (1996)
15. Sillis M, The limitations of IgM assays in the serological diagnosis of Mycoplasma pneumoniae infections, *J Med Microbiol* 33: 253-258 (1990)
16. Tuuminen T, Suni J, Kleemola M, Jacobs E, Improved sensitivity and specificity of enzyme immunoassays with P1-adhesin enriched antigen to detect acute Mycoplasma pneumoniae infection, *J Microb Meth* 44(1): 27-37 (2001)

# Symbols / Symbole / Symbôles / Símbolos / Símbolos / Σύμβολα

	Cat.-No.: / Kat.-Nr.: / No.- Cat.: / Cat.-No.: / N.º Cat.: / N.-Cat.: / Αριθμός-Κατ.:
	Lot-No.: / Chargen-Bez.: / No. Lot: / Lot-No.: / Lote N.º: / Lotto n.: / Αριθμός -Παραγωγή:
	Use by: / Verwendbar bis: / Utiliser à: / Usado por: / Usar até: / Da utilizzare entro: / Χρησιμοποιείται από:
	No. of Tests: / Kitgröße: / Nb. de Tests: / No. de Determ.: / N.º de Testes: / Quantità dei tests: / Αριθμός εξετάσεων:
	Concentrate / Konzentrat / Concentré / Concentrar / Concentrado / Concentrato / Συμπύκνωμα
	Lyophilized / Lyophilisat / Lyophilisé / Liofilizado / Liofilizado / Liofilizzato / Λυοφιλιασμένο
	In Vitro Diagnostic Medical Device. / In-vitro-Diagnostikum. / Appareil Médical pour Diagnostics In Vitro. / Dispositivo Médico para Diagnóstico In Vitro. / Equipamento Médico de Diagnóstico In Vitro. / Dispositivo Medico Diagnostico In vitro. / Ιατρική συσκευή για In-Vitro Διάγνωση.
	Evaluation kit. / Nur für Leistungsbewertungszwecke. / Kit pour évaluation. / Juego de Reactivos para Evaluació. / Kit de avaliação. / Kit di valutazione. / Κιτ Αξιολόγησης.
	Read instructions before use. / Arbeitsanleitung lesen. / Lire la fiche technique avant emploi. / Lea las instrucciones antes de usar. / Ler as instruções antes de usar. / Leggere le istruzioni prima dell'uso. / Διαβάστε τις οδηγίες πριν την χρήση.
	Keep away from heat or direct sun light. / Vor Hitze und direkter Sonneneinstrahlung schützen. / Garder à l'abri de la chaleur et de toute exposition lumineuse. / Manténgase alejado del calor o la luz solar directa. / Manter longe do calor ou luz solar directa. / Non esporre ai raggi solari. / Να φυλάσσεται μακριά από θερμότητα και άμεση επαφή με το φως του ηλίου.
	Store at: / Lagern bei: / Stocker à: / Almacene a: / Armazenar a: / Conservare a: / Αποθήκευση στους:
	Manufacturer: / Hersteller: / Fabricant: / Productor: / Fabricante: / Fabricante: / Παραγωγός:
	Caution! / Vorsicht! / Attention! / ¡Precaución! / Cuidado! / Attenzione! / Προσοχή!
<p>Symbols of the kit components see MATERIALS SUPPLIED.  Die Symbole der Komponenten sind im Kapitel KOMPONENTEN DES KITS beschrieben.  Voir MATERIEL FOURNI pour les symbôles des composants du kit.  Símbolos de los componentes del juego de reactivos, vea MATERIALES SUMINISTRADOS.  Para símbolos dos componentes do kit ver MATERIAIS FORNECIDOS.  Per i simboli dei componenti del kit si veda COMPONENTI DEL KIT.  Για τα σύμβολα των συστατικών του κιτ συμβουλευτείτε το ΠΑΡΕΧΟΜΕΝΑ ΥΛΙΚΑ.</p>	

## IBL AFFILIATES WORLDWIDE

	<b>IBL International GmbH</b> Flughafenstr. 52A, 22335 Hamburg, Germany	Tel.: + 49 (0) 40 532891 -0 Fax: -11 E-MAIL: IBL@IBL-International.com WEB: <a href="http://www.IBL-International.com">http://www.IBL-International.com</a>
	<b>IBL International Corp.</b> 194 Wildcat Road, Toronto, Ontario M3J 2N5, Canada	Tel.: +1 (416) 645 -1703 Fax: -1704 E-MAIL: Sales@IBL-International.com WEB: <a href="http://www.IBL-International.com">http://www.IBL-International.com</a>

**LIABILITY:** Complaints will be accepted in each mode –written or vocal. Preferred is that the complaint is accompanied with the test performance and results. Any modification of the test procedure or exchange or mixing of components of different lots could negatively affect the results. These cases invalidate any claim for replacement. Regardless, in the event of any claim, the manufacturer's liability is not to exceed the value of the test kit. Any damage caused to the kit during transportation is not subject to the liability of the manufacturer